Why the study?
Does AAV-5 have the capacity to package and deliver large viral genomes (≥8.2 kb) for gene therapy?
Population
Dystrophic muscle and adenovirus coinfected cells
Comparison
Adeno-associated virus serotype 5 vector… vs Regular AAV-5
Design
Preclinical
Authors
Loading...
AAV-5 lacks capacity for ≥8.2 kb genomes in this model; challenges prior reports and leaves open its utility for large gene delivery.
Does AAV-5 have the capacity to package and deliver large viral genomes (≥8.2 kb) for gene therapy?
AAV-5 does not possess the extraordinary packaging capacity (≥8.2 kb) previously reported, limiting its utility for delivering large genes such as minidystrophin in gene therapy.
Lai et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: